4503 Stock Overview
Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 4/6 |
Rewards
Risk Analysis
Astellas Pharma Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥1,558.00 |
| 52 Week High | JP¥2,360.50 |
| 52 Week Low | JP¥1,426.00 |
| Beta | 0.29 |
| 1 Month Change | -2.84% |
| 3 Month Change | -7.26% |
| 1 Year Change | -25.10% |
| 3 Year Change | -7.54% |
| 5 Year Change | 7.86% |
| Change since IPO | 164.97% |
Recent News & Updates
Astellas Pharma's (TSE:4503) Soft Earnings Are Actually Better Than They Appear
May 02
Astellas Pharma Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Apr 29Shareholder Returns
| 4503 | JP Pharmaceuticals | JP Market | |
|---|---|---|---|
| 7D | 3.5% | 4.1% | 1.4% |
| 1Y | -25.1% | 6.9% | 28.4% |
Return vs Industry: 4503 underperformed the JP Pharmaceuticals industry which returned 6.9% over the past year.
Return vs Market: 4503 underperformed the JP Market which returned 28.4% over the past year.
Price Volatility
| 4503 volatility | |
|---|---|
| 4503 Average Weekly Movement | 3.9% |
| Pharmaceuticals Industry Average Movement | 4.0% |
| Market Average Movement | 4.1% |
| 10% most volatile stocks in JP Market | 8.1% |
| 10% least volatile stocks in JP Market | 2.3% |
Stable Share Price: 4503 has not had significant price volatility in the past 3 months.
Volatility Over Time: 4503's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1923 | 14,484 | Naoki Okamura | www.astellas.com |
Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAGRAF XL immunosuppressants.
Astellas Pharma Inc. Fundamentals Summary
| 4503 fundamental statistics | |
|---|---|
| Market cap | JP¥2.79t |
| Earnings (TTM) | JP¥17.05b |
| Revenue (TTM) | JP¥1.60t |
163.9x
P/E Ratio1.7x
P/S RatioIs 4503 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4503 income statement (TTM) | |
|---|---|
| Revenue | JP¥1.60t |
| Cost of Revenue | JP¥292.49b |
| Gross Profit | JP¥1.31t |
| Other Expenses | JP¥1.29t |
| Earnings | JP¥17.05b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 9.51 |
| Gross Margin | 81.76% |
| Net Profit Margin | 1.06% |
| Debt/Equity Ratio | 57.6% |
How did 4503 perform over the long term?
See historical performance and comparison